Chimeric antigen receptor (CAR) engineered NK-92 cells expressing a CAR specific to ErbB2 (Her2) or EGFR have shown efficacy in mouse models of human RCC [59, 60], which suggest opportunities for future benefit of CAR-NK cells in patients [12, 35, 56]. This evidence concerns the gene ERBB2 and renal cell carcinoma.